EP1496851A1 - Produits de soins buccaux contenant de l'ovomucine - Google Patents

Produits de soins buccaux contenant de l'ovomucine

Info

Publication number
EP1496851A1
EP1496851A1 EP03714599A EP03714599A EP1496851A1 EP 1496851 A1 EP1496851 A1 EP 1496851A1 EP 03714599 A EP03714599 A EP 03714599A EP 03714599 A EP03714599 A EP 03714599A EP 1496851 A1 EP1496851 A1 EP 1496851A1
Authority
EP
European Patent Office
Prior art keywords
oral care
ovomucin
weight
percent
saliva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03714599A
Other languages
German (de)
English (en)
Inventor
Christine Garbers
Karin Beatrice Merck
Gijsbertus Anthonius Kleter
Johannes Maria Vereijken
Gerardus Ferdinandus Johannes Rasing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaba International Holding AG
Original Assignee
Gaba International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gaba International AG filed Critical Gaba International AG
Priority to EP10165433A priority Critical patent/EP2319489A2/fr
Publication of EP1496851A1 publication Critical patent/EP1496851A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to oral care products.
  • it relates to such oral care products in the form of saliva replacement fluids.
  • oral care products usually contain a humectant, e.g. polyhydric alcohols such as glycerin, propylene glycol, sorbitol, mannitol, glucose syrup; Polyethylene glycols, polypropylene glycols; polyvinylpyrrolidone; or cellulose derivatives such as hydroxyethyl cellulose.
  • a humectant e.g. polyhydric alcohols such as glycerin, propylene glycol, sorbitol, mannitol, glucose syrup
  • Polyethylene glycols, polypropylene glycols polyvinylpyrrolidone
  • cellulose derivatives such as hydroxyethyl cellulose.
  • Oral care products in the form of saliva replacement fluids are used in the event of insufficient natural salivation.
  • the pathological inadequate drooling referred to in technical jargon as "xerostomy” means that the affected person has trouble speaking, chewing and swallowing, for example. He often has to take a sip of water or a drink while speaking to restore the moisture in the oral cavity, but this only works for a short time. Xerostomists are more prone to infections of the oral cavity, especially the salivary ducts.
  • a saliva substitute fluid In the case of a saliva substitute fluid, not only must the moisturizing effect on the oral mucosa be achieved, but also the correct rheological behavior of the saliva substitute fluid must preferably be achieved.
  • Human saliva is a thixotropic liquid, ie its viscosity decreases with increasing shear stress. This property is important for its effectiveness as a lubricant for articulation and chewing.
  • the thixotropy of the saliva is caused by the glycoproteins (mucins) it contains.
  • the mucin found in human saliva typically has 50 to 90 weight percent carbohydrates and about 3.9 mg / 100 g sialic acid and has a molecular weight of typically about 200 to about 1000 kDa.
  • Saliva substitute liquids with different humectants and / or mucilages are available on the market. Examples of this are (in parentheses the active agent contained therein): “Glandosane” from Cell Pharm GmbH, Germany (cellulose), “Xialine” from Lommerse Pharma, Holland (xanthan resin), “Stoppers 4 Dry Mouth” from Woodridge Labs, USA ( Glycerin and Hydroxyethylcellulose), “Oral Balance” from Laclede International, Belgium (starch and
  • the mucin ovomucin has long been known as a substance (better known as a mixture of substances) (eg Robinson, DS, Monsey, JB, The Biochemical Journal 1966, 100/2, 61f., And literature cited therein). It occurs in various components of eggs, especially the egg white.
  • the raw egg white previously separated from the hail line and the egg membranes by sieving
  • the egg white is first diluted in several volumes with water and soluble proteins that dissolve.
  • the egg white fraction, salts, and other low molecular weight compounds are extracted.
  • the thick fraction of the egg clear remaining as a gel is washed with further water and / or with KCl solution, the ovomucin precipitating.
  • This ovomucin contains subunits called ⁇ - and ß-ovomucin.
  • the ⁇ -Ovomucin has N-glycosidically bound carbohydrates (approx. 15 percent by weight) and only a little sialic acid.
  • the ß-ovomucin has O-glycosidically bound carbohydrates (approx. 50 to 60 percent by weight) and a lot of sialic acid.
  • Ovomucine is therefore not a pure substance, but a substance mixture that cannot be exactly characterized and in which the actual Ovomucine glycoprotein is more or less dominant.
  • the isolated ovomucin is initially very difficult or insoluble in water.
  • the reason lies in the oxidation of thiol groups of the cysteine contained in ovomucin with the formation of disulfide groups. Cross-links are formed between the individual mucin chains, which lead to extremely high molecular weight polymers.
  • the solubilization of the ovomucin after isolation is usually effected by reducing agents such as mercaptoethanol (reduction of the disulfide bridges back to thiols) and optionally by the additional use of thiol-blocking agents such as HgCl 2 , mercury bis (p-chlorobenzoate) or iodoacetic acid.
  • reducing agents such as mercaptoethanol (reduction of the disulfide bridges back to thiols)
  • thiol-blocking agents such as HgCl 2 , mercury bis (p-chlorobenzoate) or iodoacetic acid.
  • ovomucin solutions optionally also in combination with a single additional additive, selected from lysozyme, NaCl or CaCl 2 , were examined (Hayakawa, S., Sato, Y., Agric. Biol. Chem. 1978, 42 (11), 2025-2029).
  • WO-A-99/04804 describes oral care products, for example saliva replacement fluids, which include may contain de-ovalbuminized egg white and / or aqueous extract of egg yolk.
  • WO-A-99/04804 emphasizes the importance of the immunologically active components of the egg, e.g. Lysozyme and ovotransferrin, in oral care products.
  • Ovalbumin e.g. Ovalbumin, lysozyme and ovotransferrin are known to act as allergens.
  • the object of the present invention is to provide oral care products with a good moisturizing effect on the oral mucosa, which are more favorable in terms of patient acceptance than the previously known oral care products in which mucins of animal origin provide a moisturizing effect and which entail a reduced risk of allergic reactions.
  • oral care products which comprise: a) an expectorant which contains ovomucin and has a sialic acid content of 1.5 to 2.5% by weight, and b) an emulsifier.
  • FIG. 1 is a chromatographic separation of a) an ovomucin-containing mucilage which can be used according to the invention, as produced in Example 1.
  • the conditions of the chromatography are according to Example 2.
  • X axis eluted volume, in ml;
  • Y axis optical density of the eluate, measured at 280 nm.
  • Identified compounds 1 ovomucin; 2 ovalbumin (43 kDa) and ovotransferrin (77 kDa); 3 lysozyme (14 kDa).
  • FIG. 2 is a representation of the rheological behavior of various mold-release agents at 37 ° C.
  • X-axis shear rate in revolutions per second;
  • Y axis measured viscosity in Pascal x seconds.
  • Figure 3 shows the time course of the restoration of the viscosity at 37 ° C after high shear stress.
  • X-axis time scale in seconds
  • Y-axis viscosity in Pascal x seconds. It is a) containing ovomucin Expectorant of Example 1, and b) a pork stomach mucin (obtained from Sigma).
  • FIG. 4 is a representation of the rheological behavior at 37 ° C. of two samples (rhombuses or squares) of a saliva substitute liquid (almost 2% by weight of dry matter containing ovomucin, based on the weight of the liquid) with 0.15% by weight of Cremophor® RH 410 as an emulsifier , X-axis: shear rate in revolutions per second; Y-axis: Measured viscosity in Pascal x seconds.
  • Figure ' 5 is a representation of the rheological behavior at 37 ° C of three samples (triangles, rhombuses, squares) of a saliva replacement fluid (just under 2 percent by weight dry matter ovomucin, based on the weight of the liquid) with 0.15 percent by weight Tween 20 ®.
  • Axis shear rate in revolutions per second; Y axis: Measured viscosity in Pascals x seconds.
  • the term “expectorant” means a viscosity-changing additive for oral care products.
  • oral care product is understood to mean any oral care product in which a mucilage is usually present and in which, according to the invention, an ovomucin-containing mucilage can be used instead of (or in addition to) this mucilage, the remaining additives and / or active substances can be selected by type and amount in analogy to the respective previously known oral care products.
  • oral care agents according to the invention are rinsing solutions, touching solutions and in particular saliva replacement liquids.
  • Flushing solutions according to the invention are preferably aqueous or alcoholic, particularly preferably mixed aqueous / alcoholic solutions. They can typically contain a relatively dilute concentration of an active substance, for example a conventional disinfectant such as chlorhexidine or triclosan.
  • an active substance for example a conventional disinfectant such as chlorhexidine or triclosan.
  • Typical additives for rinsing solutions in addition to the ovomucin used as a humectant and the active ingredients, are, for example, sweeteners such as saccharin, quaternary ammonium saccharinates, cyclamates, or flavorings such as coumarin and vanillin or essential oils, for example peppermint oil, spearmint oil, Anise oil, menthol, anethole, citrus oil, etc., or other flavors such as apple, eucalyptus or spearmint aroma.
  • sweeteners such as saccharin, quaternary ammonium saccharinates, cyclamates
  • flavorings such as coumarin and vanillin or essential oils
  • peppermint oil peppermint oil, spearmint oil, Anise oil, menthol, anethole, citrus oil, etc.
  • other flavors such as apple, eucalyptus or spearmint aroma.
  • Touching solutions according to the invention can be similar to the rinsing solutions, but, in analogy to the previously known touching solutions, have a relatively high amount of active agent.
  • Saliva replacement fluids according to the invention can be aqueous solutions which contain the ovomucin-containing mucilage and various salts for adjusting the tonicity, the osmolarity and the pH such that a chemical composition similar to human saliva results.
  • Such additives are chlorides of alkali or alkaline earth metals, (for example NaCl or MgCl 2 > to adjust the tonicity as well
  • Buffer substances such as phosphate or carbonate buffers that adjust the pH of the saliva replacement fluid to a pH that is physiologically acceptable in the oral cavity, but is sufficiently high to counteract the dissolution of the tooth enamel.
  • the saliva replacement fluids according to the invention also contain such additives analogously.
  • Saliva replacement fluids according to the invention therefore preferably have 0.05 to 0.15 percent by weight, particularly preferably about 0.12 percent by weight KC1; preferably 0.05 to 0.1, particularly preferably about 0.086 percent by weight of NaCl; preferably 0.002 to 0.008, particularly preferably about 0.005 percent by weight of MgCl 2 ; preferably 0.01 to 0.02, particularly preferably about 0.015 percent by weight of CaCl 2 ; and they are preferably adjusted to a pH with dihydrogen phosphate / hydrogen phosphate and / or carbonate / hydrogen carbonate buffer Buffered value and a buffer capacity that corresponds to human saliva.
  • the saliva replacement fluids according to the invention can preferably contain calcium salts in combination with phosphate in such a way that the dissolution of the tooth enamel is also counteracted.
  • the oral care products according to the invention contain only those amounts of ovalbumin, lysozyme and ovotransferrin which are present as inevitable impurities in the ovomucine-containing mucilage isolated from egg white. No further additives selected from ovalbumin, lysozyme or ovotransferrin or containing them are used in the manufacture of the oral care products according to the invention.
  • the ovomucin-containing expectorant to be used according to the invention is on the one hand the precipitate which is obtained from egg white (for example and preferably from egg white from chicken eggs) by dilution with several, typically 2 to 10 volumes of water, allowing this solution to stand for the purpose of precipitation at typically 0 ° C. to about room temperature and subsequent centrifugation can be obtained.
  • Precipitation from the aqueous solution of egg white can be achieved, for example, by adjusting the pH of the solution to approximately the isoelectric point of the ovomucin glycoprotein contained in the ovomucin (ie to approximately 4.0 to approximately 6.0, preferably to approximately 5.0 to around 6.0).
  • Mucilants containing ovomucin which can be used according to the invention can also be isolated from other constituents of eggs, in particular from the hail lines and the egg yolk membranes. These components are essentially an ovomucin with a higher degree of polymerization than the ovomucin from egg white.
  • the ovomucin from the hail lines and the egg yolk membranes is very similar to the ovomucin from egg white in terms of its chemical composition, for example the sialic acid content.
  • a mucilage from hailstones or egg yolk membranes that can be used according to the invention, these can be centrifuged beforehand, if necessary, to remove any solids (residues from eggshells) and then subjected to a wash with again typically 2 to 10 volumes of water.
  • the best possible dispersion of the ovomucin-containing mucilage is advantageously achieved, and any insoluble remnants can then advantageously be obtained by centrifugation, sedimentation or filtration be separated.
  • the ovomucin-containing mucilage isolated in this way then typically contains about 1.5 to about 2.5 grams of sialic acid per 100 grams of dry matter, preferably about 1.7 to about 2.0 grams per 100 grams of dry matter. If, based on the literature, one assumes a content of about 2 percent by weight of sialic acid for pure ovomucin, it can be assumed that the mucilage isolated in this way essentially, i.e. at least about 80 percent by weight of the dry matter, presumably even more than 90 percent by weight , consists of ovomucin.
  • the ovomucin-containing mucilage can be further cleaned by further washing with water and / or KCl solutions, as is generally known.
  • water and / or KCl solutions as is generally known.
  • an egg white mucilage containing ovomucin was investigated.
  • the further washing does not cause any further significant change in the sialic acid content or the ratio of the extinctions at 280 nm and at 214 nm (this is a measure of the residual content, in particular of lysozyme). This shows that the first time the egg clear is diluted with typically 2 to 10 volumes of water, left to stand and centrifuged, the vast majority of the foreign proteins and salts are removed.
  • the ovomucin-containing slime it is therefore not absolutely necessary to carry out further cleaning of the ovomucin-containing slime.
  • the residual lysozyme content in the expectorant and the type and amount of salts typical for a mouth-care product, in particular for a saliva replacement fluid increase the solubility of the ovomucin contained in the expectorant in the oral care products according to the invention.
  • the solubility of ovomucin can also be increased by non-toxic reducing agents for disulfide bridges such as cysteine, reducing vitamin C derivatives or NADPH.
  • the mucilage can be digested with these agents before use in the oral care products according to the invention or, in favorable cases, suitable amounts of the agents can be added directly as additives.
  • solubility of the ovomucin-containing mucilage is increased by emulsifiers, as are usually used
  • emulsifiers Dispersion of poorly water-soluble flavoring agents used in oral care products (especially synthetic emulsifiers), increased.
  • emulsifiers are anionic emulsifiers (for example alkali metal salts of fatty acids or of fatty alcohol sulfates, such as sodium lauryl sulfate) or zwitterionic emulsifiers.
  • anionic emulsifiers for example alkali metal salts of fatty acids or of fatty alcohol sulfates, such as sodium lauryl sulfate
  • zwitterionic emulsifiers examples of the latter are the amides of (C10-C 2 O) fatty acids with N ', N' -dialkyl-N '-carboxymethyl- (C 2 -C 4 ) diaminoalkylene as the amide-forming radical, the two amino groups of the diaminoalkylene being terminal are.
  • a particularly preferred example of this is cocamidopropyl betaine.
  • nonionic emulsifiers such as the poly are preferred (oxyethylene) derivatives of a partially esterified (C 3 - C 6) sugar alcohol, wherein the sugar alcohol be esterified acids (C 1 0-C20), fatty acids, which may be hydroxylated selectively in the hydrocarbon chain.
  • the fatty acids hydroxylated on the hydrocarbon chain is which preferred ricinoleic acid.
  • “Partially” esterified means, as is customary in chemistry, that at least one hydroxyl group of the sugar alcohol is not esterified.
  • the sugar alcohol is preferably glycerin, mannitol or sorbitol.
  • the number of oxyethylene units in the poly (oxyethylene) derivative can preferably be in the range from 5 to 50, preferably about 20 to about 40.
  • the poly (oxyethylene) residue is obtained, as is customary in the art, by reacting the partially esterified sugar alcohol with ethylene oxide.
  • Poly (oxyethylene) derivatives are the emulsifiers sold under the trade names Cremophor ® (e.g. Cremophor RH 410) and Tween ® (e.g. Tween 20).
  • the amounts of the emulsifiers can preferably be used in the mass ratio of ovomucin-containing mucilage to emulsifier in the range from about 10: 1 to about 1: 2, the amount ratio depending on the desired degree of dispersion of the ovomucin and / or on the possible simultaneous presence of poor water-soluble aroma substances can be determined.
  • the contents of neutral carbohydrates in the ovomucin-containing mucilage to be used according to the invention can, if desired, be determined by previously known methods.
  • the carbohydrates can be determined after acid hydrolysis (TAPPI method T 249 cm-85) and determination of the corresponding alditol acetates by means of liquid / gas chromatography (Teunissen, W., Gosselink, R.
  • JA, sounhet, F., Ovomucine which can be used according to the invention can be typical Contain 2 to 40 percent by weight of neutral carbohydrates, preferably about 20 to 35 percent by weight of carbohydrates approximately the same as the corresponding average levels of approximately 33% in ovomucin according to the literature (Robinson, DS, Monsey, JB, The Biochemical Journal 1966, 100/2, 61-62).
  • the total nitrogen content in the ovomucin-containing mucilage to be used according to the invention can be determined as usual according to the Kjeldahl method. It may typically contain about 11 to 14 weight percent nitrogen, preferably about 12 to 14 weight percent nitrogen. The total nitrogen content can be converted into a total protein content using an empirical factor of 6.25.
  • the oral care products according to the invention preferably have a thixotropy similar to human saliva in the form of saliva replacement liquids.
  • thixotropy has the usual meaning here, ie it denotes the decrease in dynamic viscosity ⁇ (in Pa 's) with increasing shear rate D (in s "1 ) at a given, constant temperature.
  • the term “thixotropy similar to human saliva” can mean that the quotient of the dynamic viscosity ⁇ of a saliva replacement fluid according to the invention and the dynamic viscosity ⁇ of human saliva for each value of the shear rate D in the range from 60 to 300 s "1 is always between about 0.1 and about 10, preferably always between about 0.3 and about 3, all measurements being carried out at 37 ° C.
  • the specified range of the shear rate is typical of the shear effects that occur within the salivary layer of the oral mucosa when Speak and chew occur.
  • Human saliva itself typically has the rheological properties listed in Table 1 at 37 ° C (mixed saliva sample from 11 human subjects, sampling time 2:00 p.m.). The measurement conditions here are the same as in the "Measurement" section of Example 3.
  • Table 1 can serve as a reference curve for the above term "thixotropy similar to human saliva".
  • mucilage containing ovomucin in the preferred oral care products according to the invention in the form of saliva replacement fluids can then typically be of the order of about 0.01 to about 2 percent by weight.
  • the oral care products according to the invention can optionally be given other mucilages, as are already known (for example carboxymethyl cellulose, hydroxyalkyl celluloses, water-soluble and swellable salts of polyacrylic acids, alginates, carraghenates, guar gum, high molecular weight polyethylene oxide, animal mucins) be added.
  • the amounts of these additional additional sliming agents can typically amount to about 0.5 to about 5 percent by weight, based on the finished oral care agent, wherein the viscosity-changing effect of such an additional sliming agent can be taken into account.
  • an abrasive containing ovomucin can be used in combination with a further expectorant in order to match the thixotropy as closely as possible to the thixotropy of human saliva.
  • the thixotropic properties of the saliva substitute fluids preferred according to the invention can under certain circumstances be fine-tuned than with ovomucine alone.
  • the additional expectorants that can be used in combination with the expectorant containing ovomucin can by themselves be thixotropic or non-thixotropic (Newtonian) solvents. generate solutions.
  • Such oral care compositions according to the invention in particular saliva replacement fluids, particularly preferably contain a combination of ovomucin-containing mucilage with mannoprotein as an additional mucilage.
  • Mannoprotein is the generic generic term for a class of polysaccharides that are an important part of the cell walls.
  • mannoproteins are the adhesins in Candida albicans and the agglutinins in Saccharomyces cerevisiae. Some of these are commercially available as partially cleaned, dried preparations and can be used directly in the form according to the invention.
  • the mannoproteins from Saccharomyces cerevisae are preferred.
  • reference can also be made to the literature eg Barriga, JAT, Cooper, DG, Idziak, ES, Cameron, DR, Enzyme and Microbial Technology 1999, 25, 96-102
  • the weight ratio of ovomucin-containing mucilage to mannoprotein in these oral care products according to the invention can be about 1: 1000 to about 10: 1, and preferably it is 1: 100 to about 2: 1.
  • Mucilant containing ovomucin and mannoprotein are preferably used in such oral care products according to the invention , in particular in saliva replacement fluids according to the invention, used in amounts such that contents (in percent by weight) of ovomucin-containing mucilage from about 0.01 to about 5% and of mannoprotein from about 0.5 to about 10% result.
  • Ovomucine-containing mucilage and mannoprotein are particularly preferably used in amounts which are about 0.05 to about Mucilage containing 1.0% ovomucin and about 2.0 to about 0.5% mannoprotein.
  • the methods mentioned above for improving the solubility of ovomucin, in particular also the emulsifiers mentioned there, can also be used in oral care products with a combination of ovomucin-containing mucilage and mannoprotein.
  • the ovomucin-containing mucilage preferably has a sialic acid content of 1.5 to 2.5 percent by weight, based on the dry matter.
  • additional humectants can preferably be added to the oral care agents according to the invention.
  • these are polyhydric alcohols such as glycerol, propylene glycol, sorbitol, mannitol, glucose syrup, polyethylene glycols or polypropylene glycols. If used, their amount can typically be about 0.5 to about 5 percent by weight based on the finished saliva replacement fluid.
  • the oral care compositions according to the invention can preferably also contain flavorings such as saccharin, quaternary ammonium saccharinates, cyclamates, cumarin, vanillin, and flavorings such as peppermint oil, spearmint oil, anise oil, menthol, anethole, citrus oil, etc., or other flavors such as apple, Eucalyptus or spearmint flavor can be added. They can typically be added in amounts of about 0.5 to about 2 percent by weight, based on the finished oral care product, whereby the strength and type of taste can be taken into account.
  • flavorings such as saccharin, quaternary ammonium saccharinates, cyclamates, cumarin, vanillin, and flavorings such as peppermint oil, spearmint oil, anise oil, menthol, anethole, citrus oil, etc., or other flavors such as apple, Eucalyptus or spearmint flavor can be added. They can typically be added in amounts of about 0.5 to about 2 percent
  • the oral care products according to the invention can also optionally contain physiologically compatible preservatives such as sodium benzoate or sorbic acid in antimicrobially effective amounts as additives.
  • physiologically compatible preservatives such as sodium benzoate or sorbic acid in antimicrobially effective amounts as additives.
  • one or more sources of fluoride ions can be added to the oral care products according to the invention.
  • these are water-soluble inorganic fluoride salts such as NaF, KF and SnF 2 , and organic ammonium fluorides such as olaflur (N'-octadecyl-N ', N, N-tris (hydroxyethyl) -1, 3-propanediamine dihydrofluoride) or the in the international patent publication WO-A-98/22427 bis- (2-hydroxyethyl) alkylammonium fluoride described.
  • These fluoride sources can be used individually or in combination.
  • the amounts of fluoride source can typically be chosen so that the finished oral care product has about 100 to about 1500 ppm free fluoride.
  • the oral care compositions according to the invention can preferably be prepared by mixing an ovomucin-containing slimy agent, in particular such a slimy agent with a sialic acid content of 1.5 to 2.5 percent by weight, with an aqueous solution comprising an emulsifier.
  • a particularly preferred method for producing the oral care products according to the invention comprises the following steps: a) The silic acid content isolated from egg whites or hail cords, from about 1.5 to about 2.5 percent by weight of the dry matter containing mucilage in an aqueous solution containing the emulsifier and any salts typical for the oral care product in terms of type and amount has, suspended, b) the suspension is stirred under high shear forces, preferably by means of a stator-rotor stirrer principle (for example an Ultraturrax®), if necessary with cooling (for example briefly several times, about 3 to 10 times each time) 5 to 10 seconds, with rest periods of 10 to 20 seconds between two stirring cycles, c) if desired, the suspension is treated with ultrasound (for example for several minutes, about 1 to 10 minutes, using about an ultrasound bath or an ultrasound probe, if desired with cooling), d) if undissolved residues of the ovomucin-containing mucilage
  • the oral care products according to the invention can be used in analogy to the previously known saliva substitute liquids and, depending on the type of oral care product, with the usual applicators such as ordinary bottles, brushes, squeeze bottles or, optionally, using a suitable propellant gas such as C0 2 , as spray solutions.
  • spray bottles can serve as applicators.
  • the oral care compositions according to the invention can be prepared only immediately before use from a solid formulation which contains the ovomucin-containing mucilage, the optional further additives and any further mucilages, and for example in the form a powder, a tablet or a troche is prepared by dissolving and diluting it in a suitable amount of water and any other solvents such as alcohol. This can be desirable if the finished oral care product does not last long enough.
  • Such dry preparations for producing an oral care product according to the invention are a further subject of the invention.
  • Example 1 Isolation of ovomucin-containing mucilage from chicken egg white
  • Freshly taken egg white from chicken eggs was dissolved in three times the volume of distilled water and the pH of the solution was adjusted to 6 with citric acid. The resulting solution was stirred at 4 ° C for 20 hours. The solution was then centrifuged for 30 min at 4 ° C. under 5500 g and the centrifugation residue was washed twice with distilled water, twice with 2% by weight KC1 in water and twice with distilled water, with 30 min at 4 ° C. after each washing solution was centrifuged under 5500 g.
  • the dry matter content of this preparation was determined by drying a weighed sample under normal pressure for 16 hours at 75 ° C. and then for 3 hours at 105 ° C.
  • the ovomucin was used in undried form, assuming the dry matter content determined in this way.
  • the product was stored at -20 ° C for longer storage.
  • a solution was prepared by dissolving an amount of ovomucin-containing slime from Preparation Example 1, which corresponded to 5 mg of dry matter, in 10 ml of water, and this solution was left to stand at 20 ° C. for 20 hours.
  • 500 ⁇ l of the solution were separated by means of gel permeation chromatography (separation according to molecular weight) on a Superose 6 column (Amersham Pharmacia Biotech, separable MG range 5 to 5000 kDa).
  • the mobile phase was 50 mM imidazole, 0.2 volume percent 2-mercaptoethanol, 0.5 weight percent Na dodecyl sulfate (SDS) in water at pH 7, the elution rate was 0.45 ml / min.
  • the eluted fractions were detected by measuring the UV absorption at 280 nm. A chromatogram as shown in Figure 1 was obtained. Since the ovomucin contained in the expectorant is eluted in the dead volume (Pike 1), it can be assumed that it has a molecular weight of at least 5000 kDa.
  • Example 3 Measurement of rheological properties of solutions with ovomucin-containing mucilage
  • a sample of the ovomucin-containing slime from Example 1 was dissolved in PBS buffer (0.2 g / 1 KH 2 P0 4 , 1.441 g / 1 Na 2 HP0 4 x 2 H 2 0, 8.5 g / 1 NaCl, 0, 1 g / MgCl 2 x 6 H 2 0, 0.2 g / 1 KC1; pH 7) by means of an Ultraturrax and with gentle stirring.
  • the weight of the ovomucin sample was such that a solution of 2 percent by weight (based on the dry weight of the expectorant) resulted.
  • the finished solution was stored at 4 ° C. overnight before the measurements.
  • the rheological measurements were carried out on a dynamic stress rheometer SR-200 (Rheometric Scientific Inc., Piscataway, USA) at 37 ° C. A 16 ml capacity chrome-coated Couette cell was used. Before the actual measurement, the sample was subjected to a pretreatment with a vision load of approximately 100 s "1 for one minute and a subsequent recovery phase of 3 minutes.
  • Example 4 Formulations for oral care agents according to the invention
  • the general manufacturing procedure for the following examples 4a to 4j was as follows:
  • the oral care products in these examples (100 g each) were prepared from up to 6 different aqueous solutions A, B, C, D, E and F.
  • Solution A (if used) contained the preservatives. To prepare solution A, the preservatives were weighed in the amounts indicated in the table of the respective example and dissolved in 10 g of purified water at 50 ° C.
  • Solution B was prepared by dissolving the amount of the ovomucin-containing gum, as prepared in Example 1, in 20 g of purified water at a maximum of 30 ° C., as stated in the respective table.
  • Solution C (if used) contained any additional humectants and mucilages (in addition to mucilants containing ovomucin).
  • additional humectants and mucilages in addition to mucilants containing ovomucin.
  • the corresponding amounts of these agents were weighed out and dissolved in 15 g of purified water with heating to a maximum of 30 ° C.
  • Solution D contained the flavorings (if used) and the emulsifiers that may be required.
  • the emulsifiers were first weighed out in the amounts indicated in the respective table and dissolved in 10 g of water. Then the weighed amount
  • Flavorings as indicated in the respective table, were added and it was dissolved with stirring.
  • Solution E contained other additives such as buffer salts, sweeteners (artificial and / or natural), colorants, agents for regulating the osmotic pressure and tonicity.
  • the additives were weighed in the appropriate amounts, as indicated in the respective table, and dissolved in 10 g of water.
  • Solution F was a stock solution of the optional fluoride ion donor NaF or Olaflur in water.
  • concentration of the stock solution was 50 mg NaF / 100 ml solution and in the case of Olaflur it was 500 mg / 100 ml solution. If a fluoride ion source was desired, an aliquot of NaF or Olaflur stock solution was used in the manufacture of the oral care products.
  • solution B was initially introduced. With stirring at room temperature, solution A (if used), then solution C (if used), then solution D (if used), then solution E, then the remaining water required for 100 g of oral care product, unless it was already used to prepare the remaining starting solutions to be used, and finally, if used, the above-mentioned aliquot of stock solution F was added. After each of the solutions had been added, the mixture was stirred until completely homogenized.
  • Example 4k the same procedure as for Examples 4a to 4j was followed, except that 10,000 g of olaflur were weighed in first and then solutions B, D, E and the remaining water were added, as indicated in the general procedure.
  • Example 5 Measurement of rheological properties in a saliva replacement fluid according to the invention
  • the suspension was first stirred with an agitator based on the stator-rotor principle (Ultraturrax IKA T25 basic, rod diameter 1.8 cm) 3 times per 20 seconds at 11500 rpm with cooling with an ice bath, with a rest period of 15 seconds between two stirring cycles lay.
  • the suspension was then sonicated by means of an ultrasound probe (Branson Sonifier 450, rod diameter 1.2 cm) 20 times for 5 seconds each with stage 6 and with cooling in an ice bath with ultrasound, with a pause of 15 seconds between each sonication.
  • 0.3 g of emulsifier (Cremophor® RH 410 or Tween® 20) added and the finished saliva substitute liquid stirred for 2 hours at room temperature. Only the supernatant of the solution was used for the measurement; According to the sialic acid content determination, at least about 80 percent by weight of the ovomucin-containing mucilage used had been dissolved.
  • the rheological measurements were carried out on a dynamic stress rheometer SR-200 (Rheometric Scientific Inc., Piscataway, USA) at 37 ° C. A 40 mm cell with chrome-plated parallel plates with a distance of 0.200 mm was used. Before the actual measurement, the sample of the saliva substitute fluid was subjected to a pretreatment with a vision load of approximately 100 s -1 for a minute and a subsequent recovery phase of 3 min. For the actual measurement, the lowest possible stresses which the measuring device was able to produce were started and the stress was increased to 50 Pa. The shear stress and the viscosity of three samples of the saliva substitute fluid prepared and pretreated in this way were measured, and the behavior was obtained as shown in FIGS. 4 and 5, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des produits de soins buccaux, en particulier des liquides de substitution de salive, qui comprennent un agent de mucus contenant de l'ovomucine ainsi qu'un émulsifiant. L'invention se rapporte en outre à des produits de soins buccaux qui comprennent un agent de mucus contenant de l'ovomucine combiné à une mannoprotéine.
EP03714599A 2002-04-25 2003-04-25 Produits de soins buccaux contenant de l'ovomucine Withdrawn EP1496851A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10165433A EP2319489A2 (fr) 2002-04-25 2003-04-25 Composition pour l'hygiène buccale contenant de l'ovomucine et de la mannoprotéine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH7072002 2002-04-25
CH7072002 2002-04-25
PCT/CH2003/000271 WO2003090703A1 (fr) 2002-04-25 2003-04-25 Produits de soins buccaux contenant de l'ovomucine

Publications (1)

Publication Number Publication Date
EP1496851A1 true EP1496851A1 (fr) 2005-01-19

Family

ID=29256408

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10165433A Withdrawn EP2319489A2 (fr) 2002-04-25 2003-04-25 Composition pour l'hygiène buccale contenant de l'ovomucine et de la mannoprotéine
EP03714599A Withdrawn EP1496851A1 (fr) 2002-04-25 2003-04-25 Produits de soins buccaux contenant de l'ovomucine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10165433A Withdrawn EP2319489A2 (fr) 2002-04-25 2003-04-25 Composition pour l'hygiène buccale contenant de l'ovomucine et de la mannoprotéine

Country Status (10)

Country Link
US (1) US20050226822A1 (fr)
EP (2) EP2319489A2 (fr)
JP (1) JP4307269B2 (fr)
AU (1) AU2003218853A1 (fr)
CA (2) CA2711709C (fr)
HR (1) HRP20041100A2 (fr)
IL (2) IL164694A (fr)
NO (1) NO20044992L (fr)
PL (2) PL393878A1 (fr)
WO (1) WO2003090703A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2905268B1 (fr) * 2006-09-01 2009-01-23 Unither Dev Soc Par Actions Si Substitut salivaire
JP5241517B2 (ja) * 2007-02-06 2013-07-17 久光製薬株式会社 アレルギー診断用マイクロニードルデバイス
FR2921260B1 (fr) 2007-09-25 2012-08-24 Lesaffre & Cie Utilisation d'un nouvel agent naturel dans des compositions cosmetiques
EP2116139A1 (fr) * 2008-05-08 2009-11-11 Nestec S.A. Acide sialique pour le support de la santé mentale des personnes âgées
SG194167A1 (en) 2011-05-16 2013-12-30 Colgate Palmolive Co Oral care composition for treating dry mouth
CN103439459A (zh) * 2013-08-16 2013-12-11 云南烟草科学研究院 一种用于新型烟草制品中烟碱及香味成分提取测定的溶媒
EP3145548B1 (fr) 2014-05-22 2022-04-13 University of Copenhagen Composition de gel aqueux et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500562A (fr) * 1980-04-25 1982-04-01
NL8402786A (nl) * 1984-09-12 1986-04-01 Stichting Biomaterials Science Preparaat voor het beschermen van gebitselementen tegen ontkalking.
US5496558A (en) * 1993-03-02 1996-03-05 Block Drug Company Inc. Solid form xerostomia product
NL9400160A (nl) * 1994-02-02 1995-09-01 Stichting Tech Wetenschapp Therapeutische samenstelling voor het vervangen en/of aanvullen van lichaamsvloeistoffen.
WO1998022427A1 (fr) 1996-11-18 1998-05-28 Gaba International Ag Fluorhydrates d'amines et leur utilisation comme agents d'hygiene dentaire
IE970541A1 (en) * 1997-07-25 1999-01-27 Michael Anthony Folan Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity
GB2361870A (en) * 2000-05-03 2001-11-07 Zia Hashmi Treating xerostomia
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03090703A1 *

Also Published As

Publication number Publication date
WO2003090703A1 (fr) 2003-11-06
US20050226822A1 (en) 2005-10-13
CA2711709A1 (fr) 2003-11-06
JP2005529125A (ja) 2005-09-29
CA2711709C (fr) 2013-03-12
JP4307269B2 (ja) 2009-08-05
AU2003218853A1 (en) 2003-11-10
NO20044992L (no) 2004-11-17
EP2319489A2 (fr) 2011-05-11
PL393878A1 (pl) 2011-05-09
CA2483000A1 (fr) 2003-11-06
CA2483000C (fr) 2011-10-11
IL164694A0 (en) 2005-12-18
IL164694A (en) 2012-10-31
IL206752A (en) 2012-12-31
IL206752A0 (en) 2011-07-31
HRP20041100A2 (en) 2004-12-31
PL371950A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
DE69836915T2 (de) Mundpflegemittel zur behandlung von übelriechendem atem
DE69737532T2 (de) ZUSAMMENSETZUNGEN ZUR KONTROLLE VON ORALEN MIKROBIELLEN OXIDATION-REDUKTION (E h) SPIEGELN
DE60037319T2 (de) Zusammensetzung zur behandlung von dentin hypersensitivität
WO2018024649A1 (fr) Composition de soins dentaires contenant de l'hydroxyapatite
IL206752A (en) Oral care products containing ovomucin and mannoprotein
US5711938A (en) Oral hygiene composition
EP0036439A2 (fr) Pâte dentifrice à haut pouvoir moussant
DE69828043T2 (de) Fluoridfreie zahnremineralisierung
DE2417872A1 (de) Zusammensetzung zur behandlung von akne oder seborrhoee
DE102006055224B4 (de) Kits, deren Herstellung und Verwendung zur aufhellenden Beschichtung von Zähnen
DE4113044A1 (de) Zahnpflegemittel
WO2019149889A1 (fr) Hydroxyapatite
DE1492085A1 (de) Mittel zur Kariesprophylaxe
DE102017009626A1 (de) Oralzusammensetzung mit Zitrusextrakt und Hydroxylapatit
DE3001575A1 (de) Mittel zur oralen hygiene
DE69915504T2 (de) Produkte für körperhygiene basierend auf lapacho extrakte enthaltend quercetin, deren herstellung und verwendung
DE102004063612B4 (de) Gelartiges Basenpräparat sowie Verwendung eines Gelbildners zu dessen Herstellung
DE102021111354A1 (de) Mundpflegemittel
DE3310180C2 (fr)
DE3225491A1 (de) Pharmazeutische zusammensetzung, ihre herstellung und verwendung
DE1667875A1 (de) Zahnpflege- und Zahnreinigungsmittel
DE2044534A1 (de) Mundpflegemittel
DE1467797A1 (de) Zahnpflegemittel
DE102018006887A1 (de) Mittel zur Mund- und Zahnpflege
DE102019104840A1 (de) Oralgel-Zusammensetzung mit Hydroxylapatit und Calciumsalz

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RASING, GERARDUS, FERDINANDUS, JOHANNES

Inventor name: VEREIJKEN, JOHANNES, MARIA

Inventor name: KLETER, GIJSBERTUS, ANTHONIUS

Inventor name: MERCK, KARIN, BEATRICE

Inventor name: GARBERS, CHRISTINE

17Q First examination report despatched

Effective date: 20090514

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GABA INTERNATIONAL AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151103